{"id":13881,"date":"2021-03-22T18:34:19","date_gmt":"2021-03-22T17:34:19","guid":{"rendered":"https:\/\/www.m-q.ch\/?p=13881"},"modified":"2021-03-23T11:32:28","modified_gmt":"2021-03-23T10:32:28","slug":"covid-19-further-vaccine-approved","status":"publish","type":"post","link":"https:\/\/www.m-q.ch\/en\/covid-19-further-vaccine-approved\/","title":{"rendered":"Covid-19: further vaccine approved"},"content":{"rendered":"
\""COVID-19
\u00a9 Depositphotos, AtlasStudio<\/figcaption><\/figure>\n

On 7 December 2020, the company Janssen-Cilag AG of the healthcare group Johnson & Johnson submitted an application to Swissmedic for authorisation of its vaccine candidate (Ad26.COV2.S). Swissmedic approves the vaccine \"COVID-19 Vaccine Janssen\" for a limited period after a careful review of all the documents submitted. Swissmedic's external expert advisory body HMEC (Human Medicines Expert Committee) supported the decision at an extraordinary meeting.<\/p>\n

Vaccine is administered only once<\/strong><\/p>\n

The vaccine is administered once (single dose) and is licensed for persons 18 years of age and older. It is based on a human adenovirus (human cold virus) that contains the blueprint of the spike proteins of the SARS-CoV-2 coronavirus, on the basis of which the desired immune response against the virus is triggered in human immune cells.<\/p>\n

The submitted study data show efficacy 14 days after vaccination in all age groups studied ranging from 64.2 % (age group 18 to 64 years) to 82.4 % (65 years and older). Severe and critical courses of Covid-19 disease can be prevented with this vaccination (at almost 85 %). In addition, a good effect was demonstrated with the mutations that dominate in Brazil and South Africa (SARS-CoV-2 variants). \u00a0<\/p>\n

The most common adverse reactions documented in the clinical trials were headache, drowsiness, pain at the injection site or nausea. Most vaccine reactions occurred within 1 to 2 days after vaccination and were of short duration (1 to 2 days).<\/p>\n

The vaccine can be stored frozen at -25 \u00b0C to -15 \u00b0C and transported frozen or thawed at 2 \u00b0C to 8 \u00b0C. After removal from the freezer, the unopened vaccine can be stored in the refrigerator for up to 3 months.<\/p>\n

Swissmedic also reviewed this marketing authorisation application at a greatly accelerated pace in a rolling procedure. Results of the ongoing studies and answers to questions posed were submitted by the company on an ongoing basis and reviewed by Swissmedic as soon as they were available.<\/p>\n

With the approval of Johnson & Johnson's Covid-19 vaccine, Swissmedic has given a positive assessment to three of the four applications for Covid-19 vaccines submitted to date. The vaccines from Pfizer\/BioNTech (Comirnaty) and Moderna have already been approved. The application from AstraZeneca is currently still under review.<\/p>\n

It should be noted that the vaccine from Johnson & Johnson has not yet been ordered by the Federal Office of Public Health. For this reason, it is unlikely to be used in Switzerland due to time constraints.\u00a0\u00a0<\/p>\n

Source: Swissmedic<\/em><\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

On December 7, 2020, Janssen-Cilag AG of the Johnson & Johnson healthcare group submitted a marketing authorization application to Swissmedic for its vaccine candidate (Ad26.COV2.S). Swissmedic approves the vaccine \"COVID-19 Vaccine Janssen\" on a temporary basis after a careful review of all submitted documents. The advisory external Swissmedic expert panel HMEC (Human Medicines Expert Committee) has approved at an extraordinary meeting the [...]<\/p>","protected":false},"author":35,"featured_media":13882,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4448],"tags":[4869,4281,4867,4868],"class_list":["post-13881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-allgemein","tag-covid-19-vaccine-janssen","tag-covid-19","tag-impfstoff","tag-johnson-johnson"],"acf":[],"yoast_head":"\nCovid-19: weiterer Impfstoff genehmigt - MQ Management und Qualit\u00e4t<\/title>\n<meta name=\"description\" content=\"Swissmedic hat den vom Pharmakonzern Johnson & Johnson entwickelten Covid-19 Impfstoff \u00abCOVID-19 Vaccine Janssen\u00bb f\u00fcr Personen ab 18 Jahren befristet zugelassen. Damit sind in der Schweiz drei Impfstoffe zur Pr\u00e4vention einer Covid-19 Erkrankung offiziell verkehrsf\u00e4hig. Der auf einem menschlichen Adenovirus basierende Vektor-Impfstoff muss nur einmal verabreicht werden. Die eingereichten Studiendaten zeigen in den untersuchten Altersgruppen eine Wirksamkeit von durchschnittlich 66,9 Prozent.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m-q.ch\/en\/covid-19-further-vaccine-approved\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covid-19: weiterer Impfstoff genehmigt - MQ Management und Qualit\u00e4t\" \/>\n<meta property=\"og:description\" content=\"Swissmedic hat den vom Pharmakonzern Johnson & Johnson entwickelten Covid-19 Impfstoff \u00abCOVID-19 Vaccine Janssen\u00bb f\u00fcr Personen ab 18 Jahren befristet zugelassen. Damit sind in der Schweiz drei Impfstoffe zur Pr\u00e4vention einer Covid-19 Erkrankung offiziell verkehrsf\u00e4hig. Der auf einem menschlichen Adenovirus basierende Vektor-Impfstoff muss nur einmal verabreicht werden. Die eingereichten Studiendaten zeigen in den untersuchten Altersgruppen eine Wirksamkeit von durchschnittlich 66,9 Prozent.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m-q.ch\/en\/covid-19-further-vaccine-approved\/\" \/>\n<meta property=\"og:site_name\" content=\"MQ Management und Qualit\u00e4t\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ManagementUndQualitaet\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-22T17:34:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-23T10:32:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Roger Str\u00e4ssle\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Roger Str\u00e4ssle\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/\"},\"author\":{\"name\":\"Roger Str\u00e4ssle\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/47d540e081acd98ccbeb69b55df653d7\"},\"headline\":\"Covid-19: weiterer Impfstoff genehmigt\",\"datePublished\":\"2021-03-22T17:34:19+00:00\",\"dateModified\":\"2021-03-23T10:32:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/\"},\"wordCount\":382,\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg\",\"keywords\":[\"\u00abCOVID-19 Vaccine Janssen\u00bb\",\"Covid-19\",\"Impfstoff\",\"Johnson & Johnson\"],\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/\",\"url\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/\",\"name\":\"Covid-19: weiterer Impfstoff genehmigt - MQ Management und Qualit\u00e4t\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg\",\"datePublished\":\"2021-03-22T17:34:19+00:00\",\"dateModified\":\"2021-03-23T10:32:28+00:00\",\"description\":\"Swissmedic hat den vom Pharmakonzern Johnson & Johnson entwickelten Covid-19 Impfstoff \u00abCOVID-19 Vaccine Janssen\u00bb f\u00fcr Personen ab 18 Jahren befristet zugelassen. Damit sind in der Schweiz drei Impfstoffe zur Pr\u00e4vention einer Covid-19 Erkrankung offiziell verkehrsf\u00e4hig. Der auf einem menschlichen Adenovirus basierende Vektor-Impfstoff muss nur einmal verabreicht werden. Die eingereichten Studiendaten zeigen in den untersuchten Altersgruppen eine Wirksamkeit von durchschnittlich 66,9 Prozent.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg\",\"width\":1000,\"height\":667,\"caption\":\"\u00a9 Depositphotos, AtlasStudio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Allgemein\",\"item\":\"https:\/\/www.m-q.ch\/kategorie\/allgemein\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Covid-19: weiterer Impfstoff genehmigt\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"name\":\"MQ Management und Qualit\u00e4t\",\"description\":\"Plattform f\u00fcr integrierte Managementsysteme.\",\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\",\"name\":\"Galledia Fachmedien AG\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"width\":512,\"height\":512,\"caption\":\"Galledia Fachmedien AG\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ManagementUndQualitaet\",\"https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/47d540e081acd98ccbeb69b55df653d7\",\"name\":\"Roger Str\u00e4ssle\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e4dde3046d8a184d2e2d27651a418883?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e4dde3046d8a184d2e2d27651a418883?s=96&d=mm&r=g\",\"caption\":\"Roger Str\u00e4ssle\"},\"url\":\"https:\/\/www.m-q.ch\/en\/author\/roger-straessle\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Covid-19: another vaccine approved - MQ Management and Quality","description":"Swissmedic has granted a temporary marketing authorisation for the Covid-19 vaccine \"COVID-19 Vaccine Janssen\", developed by the pharmaceutical company Johnson & Johnson, for people aged 18 and over. This means that three vaccines for the prevention of Covid-19 disease are officially marketable in Switzerland. The vector vaccine, which is based on a human adenovirus, only needs to be administered once. The submitted study data show an average efficacy of 66.9 percent in the age groups studied.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m-q.ch\/en\/covid-19-further-vaccine-approved\/","og_locale":"en_US","og_type":"article","og_title":"Covid-19: weiterer Impfstoff genehmigt - MQ Management und Qualit\u00e4t","og_description":"Swissmedic hat den vom Pharmakonzern Johnson & Johnson entwickelten Covid-19 Impfstoff \u00abCOVID-19 Vaccine Janssen\u00bb f\u00fcr Personen ab 18 Jahren befristet zugelassen. Damit sind in der Schweiz drei Impfstoffe zur Pr\u00e4vention einer Covid-19 Erkrankung offiziell verkehrsf\u00e4hig. Der auf einem menschlichen Adenovirus basierende Vektor-Impfstoff muss nur einmal verabreicht werden. Die eingereichten Studiendaten zeigen in den untersuchten Altersgruppen eine Wirksamkeit von durchschnittlich 66,9 Prozent.","og_url":"https:\/\/www.m-q.ch\/en\/covid-19-further-vaccine-approved\/","og_site_name":"MQ Management und Qualit\u00e4t","article_publisher":"https:\/\/www.facebook.com\/ManagementUndQualitaet","article_published_time":"2021-03-22T17:34:19+00:00","article_modified_time":"2021-03-23T10:32:28+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg","type":"image\/jpeg"}],"author":"Roger Str\u00e4ssle","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Roger Str\u00e4ssle","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#article","isPartOf":{"@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/"},"author":{"name":"Roger Str\u00e4ssle","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/47d540e081acd98ccbeb69b55df653d7"},"headline":"Covid-19: weiterer Impfstoff genehmigt","datePublished":"2021-03-22T17:34:19+00:00","dateModified":"2021-03-23T10:32:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/"},"wordCount":382,"publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"image":{"@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg","keywords":["\u00abCOVID-19 Vaccine Janssen\u00bb","Covid-19","Impfstoff","Johnson & Johnson"],"articleSection":["Allgemein"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/","url":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/","name":"Covid-19: another vaccine approved - MQ Management and Quality","isPartOf":{"@id":"https:\/\/www.m-q.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage"},"image":{"@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg","datePublished":"2021-03-22T17:34:19+00:00","dateModified":"2021-03-23T10:32:28+00:00","description":"Swissmedic has granted a temporary marketing authorisation for the Covid-19 vaccine \"COVID-19 Vaccine Janssen\", developed by the pharmaceutical company Johnson & Johnson, for people aged 18 and over. This means that three vaccines for the prevention of Covid-19 disease are officially marketable in Switzerland. The vector vaccine, which is based on a human adenovirus, only needs to be administered once. The submitted study data show an average efficacy of 66.9 percent in the age groups studied.","breadcrumb":{"@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#primaryimage","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2021\/03\/Depositphotos_340209004_s-2019.jpg","width":1000,"height":667,"caption":"\u00a9 Depositphotos, AtlasStudio"},{"@type":"BreadcrumbList","@id":"https:\/\/www.m-q.ch\/covid-19-weiterer-impfstoff-genehmigt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Allgemein","item":"https:\/\/www.m-q.ch\/kategorie\/allgemein\/"},{"@type":"ListItem","position":2,"name":"Covid-19: weiterer Impfstoff genehmigt"}]},{"@type":"WebSite","@id":"https:\/\/www.m-q.ch\/fr\/#website","url":"https:\/\/www.m-q.ch\/fr\/","name":"MQ Management and Quality","description":"Platform for integrated management systems.","publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.m-q.ch\/fr\/#organization","name":"Galledia Trade Media AG","url":"https:\/\/www.m-q.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","width":512,"height":512,"caption":"Galledia Fachmedien AG"},"image":{"@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ManagementUndQualitaet","https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/"]},{"@type":"Person","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/47d540e081acd98ccbeb69b55df653d7","name":"Roger Str\u00e4ssle","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e4dde3046d8a184d2e2d27651a418883?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e4dde3046d8a184d2e2d27651a418883?s=96&d=mm&r=g","caption":"Roger Str\u00e4ssle"},"url":"https:\/\/www.m-q.ch\/en\/author\/roger-straessle\/"}]}},"_links":{"self":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts\/13881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/comments?post=13881"}],"version-history":[{"count":3,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts\/13881\/revisions"}],"predecessor-version":[{"id":13886,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts\/13881\/revisions\/13886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/media\/13882"}],"wp:attachment":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/media?parent=13881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/categories?post=13881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/tags?post=13881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}